Skip to main content

Advertisement

Table 5 Baseline characteristics and studied parameters of the four groups along with statistical comparison

From: Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature

  Group A N = 76 Group B N = 445 Group C N = 132 Group D N = 165 p-value*
Age (mean ± SD, median, q25-q75, N) 32.96 ± 4.26, 32.5, 30–36, N = 76 33.54 ± 4.59, 34, 31–36, N = 445 37.17 ± 5.1, 37, 34–41, N = 132 32.48 ± 4.43, 32, 32–35, N = 165 <.0001
BMI (mean, SD) 24.98 ± 4.29, 23.88, 21.85–27.48, N = 76 24.38 ± 3.91, 23.51, 21.87–25.95, N = 445 24.69 ± 3.75, 24.16, 21.84–26.81, N = 130 24.44 ± 4.32, 23.51, 23.51–25.86, N = 165 0.2607
No. of foetuses at the observed gestation (N. %)
 1 73, 96.05% 434, 97.53% 102, 77.27% 158, 95.76% <.0001
  ≥ 2 3, 3.95% 11, 2.47% 30, 22.73% 7, 4.24%
Mean Duration of LMWH (months) 8.67 ± 1.7, 9, 9–9.5, N = 74 8.73 ± 1.32, 9, 9–9.5, N = 445 8.69 ± 1.7, 9, 9–9.5, N = 131 8.31 ± 1.61, 9, 9–9, N = 162 <.0001
ASA Duration 6.73 ± 2.76, 8, 6–9, N = 11 6.1 ± 2.38, 7, 3–8, N = 79 5.46 ± 2.79, 7, 3–8, N = 39 7.89 ± 1.97, 8, 8–9, N = 19 0.0068
Fixed Prophylactic Dose 26, 34.21% 262, 58.88% 66, 50% 86, 52.12% <.0001
Weight Adjusted prophylactic dose 16, 21.05% 144, 32.36% 51, 38.64% 61, 36.97%
Therapeutic dose of LMWH 34, 44.74% 39, 8.76% 15, 11.36% 18, 10.91%
Concomitant Use of ASA (N, % women rceived ASA within the group) 11, 14.47% 81, 18.2% 40, 30.3% 20, 12.12% 0.0006
Caesarian 61, 80.26% 354, 79.73% 121, 91.67% 108, 65.45% <.0001
Live Birth 74, 97.37% 441, 99.1% 128, 96.97% 164, 99.39% 0.1632
High risk Thrombophilia (positive cases) 19, 25% 45, 10.11% 13, 9.85% 17, 10.3% 0.0018
APA status (total successful tests N = 363) (positive cases, % within group)) 16, 29.63% 57, 29.08% 16, 27.12% 11, 20.37% 0.6264
  1. * p-value is for Kruskal-Wallis test for numerical parameters and for x-square test for categorical parameters